Form 8-K - Current report:
SEC Accession No. 0001193125-20-036011
Filing Date
2020-02-14
Accepted
2020-02-13 20:45:33
Documents
9
Period of Report
2020-02-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d870581d8k.htm 8-K 24680
2 EX-1.1 d870581dex11.htm EX-1.1 177545
3 EX-5.1 d870581dex51.htm EX-5.1 8877
4 EX-99.1 d870581dex991.htm EX-99.1 7654
5 EX-99.2 d870581dex992.htm EX-99.2 8115
6 GRAPHIC g870581g0212124241091.jpg GRAPHIC 1595
7 GRAPHIC g870581g0212124430993.jpg GRAPHIC 1595
8 GRAPHIC g870581g0212222549010.jpg GRAPHIC 2357
9 GRAPHIC g870581g0212222550071.jpg GRAPHIC 2410
  Complete submission text file 0001193125-20-036011.txt   239767
Mailing Address 611 GATEWAY BLVD., SUITE 710 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 710 SOUTH SAN FRANCISCO CA 94080 650-871-0761
CATALYST BIOSCIENCES, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 20613173
SIC: 2834 Pharmaceutical Preparations